Home Latest Articles
Latest Articles
  • Jie HE, Jianxin HU, Zhiyou LI, Bin YUAN, Liming JIA
    World Clinical Drug. 2025, 46(1): 73-80.
    Objective

    To explore the role and existing problems of centralized drug procurement policies in balancing medical, pharmaceutical, and medical insurance costs, ensuring safe and rational use of drugs by the public, and promoting the healthy development of the pharmaceutical industry.

    Method

    The relevant policies, literature, cases, and data were analyzed, and the impact and response of policies on various stakeholders and their reactions were interpreted from multiple dimensions.

    Result

    The policy of centralized drug procurement was formed during the period of China's economic marketization reform and medical and health system reform. While promoting the construction of the drug supply guarantee system, the policy has promoted the reform of the compensation mechanism of public hospitals and the medical service prices, promoted the balance of medical insurance funds and the modernization of the medical and health governance system. At present, centralized drug procurement has problems in policy implementation, quality improvement and expansion, slow adjustment of medical service prices, and increased difficulty in balancing the interests of the public, medicine, medical development, and fund security. It is necessary to improve the unified and efficient policy linkage and management coordination mechanism of medical insurance, healthcare, and medicine, and promote "value medicine".

    Conclusion

    The policy of centralized drug procurement and the reforms related to medicine, healthcare, and medical insurance are mutually causal and synergistic, promoting the modernization process of the governance system and governance capacity of the medicine, healthcare, and medical insurance.

  • Zhiyou LI, Jianxin HU, Jie HE, Bin YUAN, Liming JIA
    World Clinical Drug. 2025, 46(1): 81-86.
  • Zile YAN, Qingqiang LEI, Min HU
    World Clinical Drug. 2025, 46(1): 87-94.
    Objective

    To systematically review the literature on the accessibility of national medicare negotiated drugs and summarize its improvement.

    Methods

    CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science were searched to collect published literature about national medicare negotiated drugs accessibility, and analyze the content of the literature.

    Results

    25 literatures were included, of which 17 focus on the impact of national medicare negotiated drugs accessibility, while the remaining 8 research the current status of national medicare negotiated drugs accessibility after the policy. Regarding availability, all of the literature found that the policy had a significant positive effect on the uptake of drugs, while 40%(10/25) found that there were some regional or institutional differences in the availability. Regarding affordability, only 60%(15/25) of the literature noted a sharp decrease in the price of national medicare negotiated drugs after the policy. However, 27%(4/15) mentioned that the out-of-pocket costs of most anticancer drugs were still high.

    Conclusion

    The National Price Negotiation policy has effectively improved drug accessibility, but it is still necessary to continuously promote the use of national medicare negotiated drugs and to improve the treatment of medicines in health insurance.

  • Hao JIANG, Yuhao WANG, Wei XU
    World Clinical Drug. 2025, 46(1): 95-103.

    Diagnosis-intervention packet(DIP) is a payment method with Chinese characteristics proposed by combining payment by disease with regional total budget and points. It is currently one of the hospitalization payment methods being promoted in China. This study collected literature on the practical effects of DIP, and used literature hotspot analysis and system review method to summarize the trend of DIP research hotspots and the comparison of effects before and after policy implementation, and put forward the relevant suggestions to improve the research on DIP.

  • Muzhi LI, Sicun WANG, Haixia DANG, Jun LIU, Zhong WANG, Ya'nan YU
    World Clinical Drug. 2024, 45(12): 1213-1218.

    The holistic concept of traditional Chinese medicine (TCM) pays more attention to the ''sick person'', that is ''patient-centered diagnosis and treatment strategies''. The most recent iteration of the Measures for the Administration of Drug Registration points out that the therapeutic evaluation of TCM should select the indicators that align with the clinical principles and showcase its unique functional characteristics and advantages. At the same time, under the continuous promotion of modern evaluation systems, there has been a notable increase in innovative clinical trial methods of TCM. There is a growing trend towards utilizing more flexible and expedited clinical trial designs throughout the drug product lifecycle to enhance efficiency of the trials based on rational utilization. This paper took the clinical research of Di'ao Xinxuekang capsule in the treatment of chronic stable angina pectoris as an example, introducing the practical exploration of combining patient-centered clinical research approach with adaptive design, providing useful reference for the evaluation of TCM efficacy.

  • Jun LIU, Nian WANG, Yanan YU, Zhong WANG
    World Clinical Drug. 2024, 45(12): 1219-1225.

    Traditional Chinese medicine (TCM) plays an important role in ensuring the health of the people, and its efficacy is a core reflection of its clinical value and significance. A scientific, detailed, and clear clinical trial protocol is of great significance for accurately assessing the clinical efficacy of drugs, which can fully reflect their clinical value, ensure the scientific, reliable, and accurate nature of clinical trials, and ultimately guarantee their successful completion. This article followed the design principles of clinical trial protocols, combined with the rich experience accumulated by our team in long-term clinical trial practice. From the perspective of how to reflect the clinical value of drugs, the determination of the purpose and the clinical positioning of the drug clinical trials, the selection of participants and the controls, the setting of corresponding statistical boundary values for clinical trial were discussed. And the selection of clinical efficacy outcomes which could reflect the clinical value and clinical significance of the drugs, the key design elements of clinical trial protocols - ''PICOS'' principle were comprehensively and deeply analyzed and discussed, aiming to provide a scientific, reasonable, and practical reference for the design of TCM clinical trial protocols that emphasize clinical value.

  • Sicun WANG, Muzhi LI, Haixia DANG, Jun LIU, Zhong WANG, Ya'nan YU
    World Clinical Drug. 2024, 45(12): 1226-1234.

    The disability caused by stroke is a serious public health problem that causes a heavy burden to the society. The convalescence of stroke disability is the key stage of functional recovery, but there is no effective drug treatment at present. In recent years, traditional Chinese medicine (TCM) has significant potential in the field of drug research and development. Based on the guidelines for the diagnosis and treatment of stroke recovery at home and abroad in recent years, combined with the current clinical research situation and potential problems of TCM research and development, this paper discussed the key link in the process of clinical research design, including clinical positioning, efficacy indicators, clinical test control, treatment course, and visiting perspective, and takes the clinical trial of Qizhi Tongluo capsule as an example to explain, aiming to provide objective and operable design elements for the majority of researchers in the field of TCM to carry out high-quality clinical research.

  • Hui HUANG, Jiahui XU, Mengjie CAI, Hao LU, Fan GONG
    World Clinical Drug. 2024, 45(12): 1235-1244.
    Objective

    To explore the mechanism of Jianpi Qinghua formula in improving catecholamine resistance in obesity by network pharmacology and molecular docking techniques.

    Methods

    The main active components and related targets of Jianpi Qinghua formula were screened by the database of traditional Chinese medicine system pharmacology and analysis platform. Catecholamine resistance targets associated with obesity were screened by the online human Mendelian genetics and GeneCards databases. The network topology diagram of "Jianpi Qinghua formula-active ingredient-target" and the protein-protein interaction network diagram were constructed by Cytoscape3.7.1 software to identify key targets. The intersection targets were imported into DAVID database for bioinformatics analysis. AutoDock Vina was used for molecular docking to screen and further verify the core chemical components of the formula.

    Results

    A total of 79 active ingredients and 661 targets were screened in the formula. A total of 1 337 catecholamine resistance targets and 262 intersection targets were identified in obesity. The key targets were signal transducer and activator of transcription 3, caspase 3, B-cell lymphoma-2 and serine-threonine kinase 1 (AKT1). The results of the analysis of the Kyoto Encyclopedia of Genes and Genome showed that the improvement of catecholamine resistance by Jianpi Qinghua formula in obesity was related to the neuroactive ligand-receptor interaction, phosphatidylinositol-3-kinase/AKT1 signaling pathway and cyclic adenosine monophosphate signaling pathway.

    Conclusion

    The core components of Jianpi Qinghua formula of the potential mechanism may be 4',5-dihydroxyflavone, baicalein and jaranol in improving catecholamine resistance in obesity.

  • Chunmei WANG, Min GUO, Yiwen CAO, Genlin WANG
    World Clinical Drug. 2024, 45(12): 1245-1251.
    Objective

    To explore the effects of Sihong Quban decoction combined with photon skin rejuvenation technology on the degree of skin lesions and sebum content in patients with chloasma.

    Methods

    One-hundred patients diagnosed with chloasma in our hospital from September 2021 to September 2023 were collected and randomly separated into conventional group and combination group, with 50 cases in each group. The conventional group was treated with photon skin rejuvenation technology, while the combination group was treated with Sihong Quban decoction combined with photon skin rejuvenation technology. The clinical efficacy, degree of skin lesions, skin indicators, oxidative stress indicators, serum sex hormone indicators, and adverse reactions were observed after treatment.

    Results

    After treatment, the total effective rate of the combination group was 96.00%, the conventional group was 76.00%, and the combination group was obviously higher than the conventional group (P<0.05). The skin color score, skin lesion area score, total skin lesion score, sebum content of skin lesions, pigmentation, pores, wrinkles, melasma area severity index score, malonaldehyde, follicle-stimulating hormone, luteinizing hormone, and estradiol levels of the two groups were obviously reduced compared to before treatment, and the above indicators (except for sebum content) in the combination group were obviously lower than those in the conventional group (P<0.05). There was no obvious difference in sebum content between the two groups (P>0.05). The skin moisture content, skin elasticity index, superoxide dismutase (SOD) and catalase (CAT) levels in both groups were obviously increased compared to before treatment (P<0.05), and the combination group had obviously higher skin moisture content, skin elasticity index, SOD and CAT levels than the conventional group (P<0.05). There was no significant difference in adverse reaction rate between the two groups during treatment (P>0.05).

    Conclusion

    Sihong Quban decoction combined with photon skin rejuvenation technology can improve clinical efficacy, reduce skin lesions and oxidative stress response, improve skin condition, and regulate serum sex hormone levels in patients with chloasma.

  • Xiujuan HAN, Yanhui LI, Chaomin SHI
    World Clinical Drug. 2024, 45(12): 1252-1257.
    Objective

    To investigate the effect and safety of Chinese and western medicine regimen containing centipede on clinical symptom and sign score, CT score and lung function in patients with interstitial lung disease (ILD).

    Methods

    A total of 102 patients with ILD who treated in our hospital from January 2021 to June 2022 were selected as the research objects and divided into the control group and the combined group, with 51 cases in each group. The control group was treated with standard western medicine, and the combined group was treated with standard traditional Chinese medicine containing centipede on the basis of the control group. The curative effect, clinical symptoms and signs scores, CT scores, and forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCO) after treatment were compared between the two groups.

    Results

    The total effective rate of the combined group was higher than that of the control group (P<0.05). After 3 months of treatment, the CT score of the control group was (9.25±2.42) points, and the combined group was (7.26±1.48) points, the difference between the two groups was statistically significant (P<0.05). The scores of clinical symptoms such as cough, asthma and fatigue in the combined group were lower than those in the control group (P<0.05). After 3 months of treatment, the FVC and DLCO of the combined group were higher than those of the control group (P<0.05). During treatment, the incidence of oral infection, arrhythmia, hoarseness and other adverse reactions in the combined group was 11.76%, which was not significantly different from 9.80% in the control group (P>0.05).

    Conclusion

    The Chinese and western medicine treatment regimen containing centipede can improve the treatment effect of ILD patients, reduce clinical symptoms and signs such as cough and fatigue, improve lung function, and has high safety.

News